tegretol no tratamento da epilepsia tegretol in the treatment of epilepsy

tegretol no tratamento da epilepsia tegretol in the treatment of epilepsy

;Jorge Armbrust-Figueiredo
communications in computer and information science 1968 Vol. 26 pp. 223-228
112
armbrust-figueiredo1968arquivostegretol

Abstract

O Tegretol (5-carbamil-5H-dibenzo-b,L-azepina) foi usado no tratamento de 68 pacientes com epilepsia; 54 apresentavam epilepsia temporal (42 com crises psicomotoras e 12 com crises complexas), 11 epilepsia focal de projeção não temporal e 3 epilepsia centrencefálica com crises P.M. Resultados satisfatórios foram observados em 82% dos 65 pacientes com epilepsia focal; os 3 pacientes com crises P.M. não foram influenciados pelo tratamento. A ação sobre as manifestações psíquicas que acompanhavam o quadro crítico ou intercrítico das crises ficou bem evidenciada. Os pacientes melhoraram de seus sintomas na grande maioria dos casos, conseguindo adaptar-se melhor no ambiente familiar, profissional e escolar. O efeito sobre as alterações eletrencefalográficas é moderado, e a evolução clínica não acompanha as modificações dos traçados. As doses usadas, em geral de 400 a 600 mg diários, são suficientes para o controle das crises na maioria dos casos e estão muito abaixo dos limites considerados como de segurança. As reações secundárias foram observadas em pequeno número de casos e foram sempre transitórias. O Tegretol representa, em nossa opinião, recurso de valor no trataemnto das epilepsias focais, particularmente nas crises psicomotoras.
Tegretol (5-carbanyl-5H-dibenzo-b,L-azepina) was used experimentally in the theatment of 68 epileptic patients; 54 had temporal lobe epilepsy (42 had psychomotor and 12 had complex seizures), 11 had focal non-temporal lobe epilepsy and 3 had P.M. epilepsy. Satisfactory results were obtained in 82 per cent of the 65 patients with focal epilepsy, but failure of the treatment was observed in all cases of P.M. epilepsy. The drug has a very good influence on the critical and intercritical mental phenomena which are frequently present in these patients. The personality of the patient improves and he becomes better adjusted to his family, his work or school. The action of the electroencephalogram is not very clear. Some records were improved, others remained inaltered. The dosage used varied from 400 to 600 mg daily in the great majority of cases. Side effects were not common and not severe. One patient developed transitory drop in leukocytes. Tegretol is a drug with anticonvulsivant and psychotropic properties, and has a very pronounced effect on focal epilepsy particularly on psychomotor seizures.

Citation

ID: 145106
Ref Key: armbrust-figueiredo1968arquivostegretol
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
145106
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet